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S U M M A R Y
Objective: The objective of this study was to determine the frequency of dhfr and dhps resistance-
associated haplotypes in Plasmodium falciparum isolates, three years after the introduction of
sulfadoxine–pyrimethamine (SP) as the ﬁrst-line antimalarial treatment in Iran.
Methods: Blood samples (N = 182) were collected from patients presenting with falciparum malaria
from southeastern Iran, and analyzed by nested-PCR/restriction fragment length polymorphism,
followed by sequencing analysis.
Results: In pfdhfr, double mutation at positions 59R and 108N was a predominant allele with a
prevalence of 95.7%. The pure double mutations of pfdhfr (I51N108) were detected, and showed an
increase from 0.7% to 4.3% after the introduction of SP as ﬁrst-line drug. Furthermore, a signiﬁcant
decrease in double mutations/wild-type of pfdhfr/pfdhps (R59N108/A437) was observed from 2004 (83.5%)
to 2008 (44%) after changes in treatment policy. With regards to pfdhps, the results showed a rapid
increase in frequency of the single pure form of pfdhps at position 437G (54.4%) and that of triple pfdhfr/
pfdhps (R59N108/G437) mutant haplotype (51.7%) after three years.
Conclusions: The absence of quintuple mutations in the examined isolates supports the continued use of
SP as the treatment of choice for uncomplicated malaria as a partner drug to artemisinin combination
therapy in Iran. However, the increase in the triple pfdhfr/pfdhps (R59N108/G437) mutant haplotypes
indicates that the P. falciparum parasite populations have the potential to evolve into dhfr/dhps quintuple
mutants in the near future. Therefore, monitoring the status of dhps alleles as a predictor of the
development of clinical resistance to sulfadoxine should be a high priority in this region.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Attempts to control malaria have been hampered because of
resistance in Plasmodium falciparum to the most commonly used
drugs, such as chloroquine (CQ). Increasing CQ resistance has
resulted in sulfadoxine–pyrimethamine (SP) becoming the ﬁrst-
line drug for the treatment of uncomplicated malaria in several
countries. However, SP has a short useful therapeutic life,1–3 and
when SP is widely used, resistance develops relatively quickly.
Therefore, theWorld Health Organization (WHO) recommends the
use of combination therapies of two or more drugs that target
different pathways to overcome resistance, in particular artemi-
sinin combination therapies (ACTs).4* Corresponding author. Tel.: +98 21 66480780; fax: +98 21 66465132.
E-mail addresses: zakeris@yahoo.com, zakeris@pasteur.ac.ir (S. Zakeri).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.035Molecular markers of SP resistance are based on mutations
in the parasite’s dihydrofolate reductase (dhfr) and dihydrop-
teroate synthase (dhps) genes.3,5 SP acts as a synergistic
inhibitor of folate biosynthesis, which is an obligatory require-
ment for the production of nucleotides, and hence DNA
synthesis, in malaria parasites. A dhfr codon, Asn108 with
Ile51 and Arg59, confers resistance to pyrimethamine and may
predict SP treatment failure in some malaria areas. For dhps, the
Gly437 mutant is associated with sulfonamide resistance, while
additional mutations in the Ala436, Glu540, Gly581 and Ser613
codons appear to increase the degree of resistance. These
mutations cause alterations in key amino acid residues in the
active sites of these enzymes, which reduce the afﬁnity of the
enzyme for the drug.6–13 Increased numbers of mutations in
pfdhfr and pfdhps are associated with increased levels of
resistance to SP.ses. Published by Elsevier Ltd. All rights reserved.
S. Zakeri et al. / International Journal of Infectious Diseases 14S (2010) e123–e128e124Malaria is a serious health problem in Iran. In the last decade
(1990–1999), the number of annual malaria cases decreased from
96 340 in 1991 to around 16 000 in 2007. Malaria transmission
mostly occurs in the southeastern parts of the country, in Sistan
and Baluchistan Province, Hormozgan Province, and the tropical
areas of Kerman Province. P. falciparum is prevalent and
responsible for 10–20% of malaria cases. Resistance of P. falciparum
to CQ has increased since it was ﬁrst reported in Sistan and
Baluchistan Province in 1983,14 and currently accounts for more
than 78.5% of treatment failures in the southeastern provinces of
Iran.15 Resistance to SP has been conﬁrmed in malaria-endemic
areas of Iran by in vitro and in vivo tests.16 In 2005, as the intensity
of CQ resistance increased, the country implemented a change in
the ﬁrst-line antimalarial treatment to a combination of SP/CQ,
with artemether–lumefantrine (Coartem1) as the second-line
drug.17 Although SP has remained the treatment of choice for
uncomplicated malaria, the high rates of treatment failure seen
with CQ,17 and therefore the inadequate efﬁcacy of treatment with
the SP/CQ combination, resulted in a decision by the Center for
Disease Management and Control to revise its treatment policy
again in 2007, and SP/CQ was replaced with SP/artesunate as the
ﬁrst-line recommendation for falciparum malaria. As a result,
there has been an increase in the use of SP in the country, exposing
P. falciparum isolates to drug pressure, which may result in the
rapid emergence of SP resistance due to selection.18,19 Therefore,
molecular surveillance is necessary to detect the emergence of
resistance mutations.
The objective of this study was to determine the frequency of
dhfr and dhps resistance-associated haplotypes in P. falciparum
isolates, three years after the introduction of SP as a partner drug in
the ﬁrst-line treatment of malaria in Iran. This investigation is also
a follow-up study to our previous work in the same area.20
2. Materials and methods
2.1. Study areas and sample collection
The Chabahar districts of Sistan and Baluchistan Province, in the
southeastern part of Iran were selected as the study area. In this
region, malaria transmission is year-roundwith two peaks: the ﬁrst
from May to August, with Plasmodium vivax as the predominant
species, and the second from October to November, when both P.
falciparumandP. vivax infectionsare recorded. FromOctober2005to
October 2008, blood samples (N = 182)were collected onday0 from
uncomplicated P. falciparum-infected patients of Iranian, Afghani
and Pakistani nationality, aged from 1 to 75 years. The inclusion
criteria were as follows: presence of fever for the preceding 48 h
(axillary temperature 37.5 8C), mono-infection with P. falciparum,
no intake of antimalarial drugs in the preceding 4weeks, no signs of
complications, no history of allergic reactions to SP, and informed
consent from patients or their parents.
Thin and thick blood ﬁlms were stained with Giemsa and
examined microscopically for the detection of the P. falciparum
parasite. Approximately 1 ml venous blood was obtained in a tube
containing EDTA from the patients who were conﬁrmed to be
positive for the presence of P. falciparum parasites. All patients
were then treated with SP plus either CQ (before 2007, n = 82) or
artesunate (after 2007, n = 100), as the ﬁrst-line drug and, if
needed, with Coartem as the second-line antimalarial drug for the
treatment of uncomplicatedmalaria cases. The patientswere given
oral SP (FansidarTM, 25 mg/kg sulfadoxine and 1.25 mg/kg
pyrimethamine) as a single dose on day 0 under supervision.
Treatment was completed with CQ 10 mg/kg on day 0 and day 1
and a 5 mg/kg dose on day 2, or artesunate taken as three doses of
tablets (4 mg/kg) given on days 0, 1, and 2. The consumption of
each dosewas observed by one of the primary healthcare staff (as amember of the study team) and physical complaintswere recorded
at the time of each visit.
2.2. In vivo assay
In this investigation, 75/182 patients aged 10 to 50 years
(median 25 years), presenting to the outpatient clinic with an
attack of non-severe malaria, were enrolled for 28 days of follow-
up according to the WHO protocol.21 We excluded subjects
meeting the WHO criteria for severe or complicated malaria,
pregnant women, children aged less than 5 years, those suffering
from malnutrition, those with a severe allergic reaction to the
study drugs, those with the onset of a non-malaria febrile illness
during follow-up, those with persistent vomiting, those self-
medicating with antimalarials during follow-up, and those who
withdrew consent. A medical history was taken and clinical
examination made for all eligible patients. A ﬁnger-prick blood
sample was obtained to measure parasite density. Approximately
1 ml venous blood was obtained pre-treatment (day 0) in a tube
containing EDTA from patients who were conﬁrmed to be positive
for the presence of P. falciparum parasites. The patients were then
given oral SP (Fansidar, 25 mg/kg sulfadoxine and 1.25 mg/kg
pyrimethamine) as a single dose on day 0 under supervision.
Treatment was completed with three doses of artesunate (4 mg/
kg) on days 0, 1 and 2. The consumption of each dose was observed
by one of the primary healthcare staff as a member of the study
team. The patients were asked to return on days 7, 14, 21, and 28
following treatment (post-treatment). Parasite clearance was
monitored by thick ﬁlm microscopy each day after treatment.
Treatment outcomes were classiﬁed according to the WHO
guidelines as early treatment failure (ETF), late clinical failure
(LCF), late parasitologic failure (LPF), or adequate clinical and
parasitological response (ACPR). The study was reviewed by, and
received ethical clearance from, the Pasteur Institute of Iran. All
blood samples were collected in a tube containing EDTA, stored at
4 8C, and then transported to the main laboratory in Tehran.
2.3. Parasite DNA extraction
The parasite genomic DNA was extracted from infected red
blood cells using phenol/phenol–chloroform followed by ethanol
precipitation, as described previously.22
2.4. Nested polymerase chain reaction ampliﬁcation of pfdhfr and
pfdhps genes
Nested PCRs were performed for dhfr and dhps genes, and all
reactions were carried out in reactionmixtures of 25ml containing
1.5–3 mMMgCl2, 200mM dNTP mixture (Invitrogen, Carlsbad, CA,
USA), 1 unit Taq polymerase (Invitrogen, Carlsbad, CA, USA), and a
pair of primers (10 pmol each). For both dhfr and dhps, 1 or 2ml
DNA was used as template in the ﬁrst reaction, and for the second
reaction, 1ml of ﬁrst PCR product was used if no band was seen
from the ﬁrst round PCR product. However, in the case of an
intense band, 1 ml of a 1/100 dilution of the samples was used as
template for secondary PCR. Negative controls (ddH2O) were used
in all PCRs. The PCR primers and the modiﬁed conditions for both
genes have been described previously.20,23 Secondary PCR
products were resolved by electrophoresis on 1–2% agarose gels
and visualized by staining with ethidium bromide.
2.5. Restriction fragment length polymorphism (RFLP) of pfdhfr and
pfdhps genes
Mutation-speciﬁc restriction endonuclease digestion was used
to detect single nucleotide polymorphisms (SNPs) in dhfr at
Table 1
The frequency distribution of SNP combinations of pfdhfr and pfdhps alleles associated with sulfadoxine–pyrimethamine resistance in clinical isolates of Plasmodium
falciparum in southeastern Iran, three years after changing the ﬁrst-line antimalarial drug
pfdhfr pfdhps 2005–2008
N51I C59R S108N I164L S436A/F A437G K540E A581G A613S/T
N R N I S A K A A 80 (44%)
N R N I S G K A A 94 (51.7%)
I C N I S A K A A 3 (1.6%)
I C N I S G K A A 5 (2.7%)
I =4.3% R=95.7% N=100% – – G=54.4% – – – n=182
SNP, single nucleotide polymorphism.
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A436F/A, A437G, K540E, A581E, and A613S/T.20,23 A number of
restriction enzymes were used for RFLP of PCR products. For dhfr,
the PCR products were digested with TasI and TaqI to determine
the polymorphisms at codons 51 and 59, respectively. Three
enzymes, AluI, BsrI, and MvaI, were used to identify wild and
mutant dhfr allele at codon 108, and DraI was used to detect
mutation at position I164L. For dhps, the PCR products were
digested with HhaI, MnlI and HindIII to determine the polymorph-
isms at codon 436, AvaII and MwoI at codon 437, FokI, BstUI, and
MwoI at codons 540, 580, and 613, respectively. Digestions were
done in 20 ml reactions containing 10 ml PCR fragments according
to the manufacturer’s instructions (New England Biolab, Beverly,
MA, USA; Roche, Germany; Invitrogen, Carlsbad, CA, USA).
Digested products were subjected to electrophoresis on 1.5–2%
agarose or 2–3% Metaphor agarose gels, and visualized by
ultraviolet (UV) transillumination.
2.6. Nucleotide sequencing of pfdhfr and pfdhps
Sequence analysis was used to identify polymorphisms in pfdhfr
and pfdhps ampliﬁed from 10 ﬁeld samples. The PCR products were
gel-puriﬁed using the Qiagen DNA puriﬁcation kit (Qiagen,
Germany) following the manufacturer’s instructions. DNA sequen-
cing was carried out using the dideoxy chain termination
procedure (Chemistry V3.1, Applied Biosystems) and the 3730XL
DNA analyzer (Applied Biosystems) by MilliGen sequencing
service (Labe`ge, France).
For the whole gene of dhfr and dhps, the following sequencing
primers were used so as to obtain overlapping sequences that span
the whole gene: pfdhfr (accession number: J03028): dhfrF1:
ATGATGGAACAAGTCTGCG; dhfrR1: TTGTCATCATTCTTTAAAGGC;
dhfrF2: TCCAGAAATAAATGAAAATGAG; dhfrR2: ACCATAAA-
TAGGTCCTAAATCG; dhfrF3: AGAATGTAAGGATATGGGAAG;Table 2
Distribution of pfdhfr/pfdhps polymorphisms based on nested-PCR/RFLP in clinical sam
pfdhfr pfdhps
N51I C59R S108N I164L S436A/F A437G K540E
N R N I S A K
N R N I S G K
I C N I S A K
I C N I S G K
N C N I S A K
N C/R N I S A K
N R S/N I S A K
N/I R N I S A K
N R N I S A/G K
N/I R N I S A/G K
RFLP, restriction fragment length polymorphism.
a The double mutations of pfdhfr (I51N108) were detected and showed an increase from
drug. There was also a rapid increase in frequency of the single pure form of pfdhps at p
three years after the introduction of sulfadoxine–pyrimethamine as the ﬁrst-line drugdhfrR3: AGGTAATTTTGTCATCATTTG. pfdhps (accession number:
XM-001349382): dhpsF1: TGCTTAAATGATATGATACCC; dhpsR1:
ATTTCCTCTTTTATGCATTAG; dhpsF2: TAGTGCTTGTACAAATAATC-
CAG; dhpsR2: ATCACATGTTTGCACTTTCC.
2.7. Statistical analyses
All statistical analyses were performed using SPSS statistical
package version 15.0 (SPSS Inc., Chicago, IL, USA). Frequencies of
mutations and haplotypes among groupswere compared using the
Chi-square test. A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. In vivo study
In this study, 75 out of 100 P. falciparum-infected patients who
received SP/artesunate completed the 28 days of follow-up. The
median age of the 75 patients was 25 years (range 10–50 years)
and parasitemia ranged between 1000 and 35 000 asexual
parasites/mm3. SP/artesunate treatment gave ACPR in 75 (100%)
subjects. All follow-up blood samples collected were also negative
for Plasmodium species by PCR assay.
3.2. pfdhfr and pfdhps genotypes
All 182 P. falciparum isolates were successfully genotyped for
detection of dhfr and dhps mutations associated with SP
resistance. P. falciparum isolates were found to carry the mutant
type 108N (100%), and 95.7% of them carried the 59R mutation;
however, the 51I mutation was present in 4.3% of examined
samples (Table 1). Themajority of the patients (95.7%)were found
to carry both 59R and 108N in pure form (only mutant genotypeples collected from Chabahar districts during 2000–2008.a
Year
A581G A613S/T 2000–2002 2003–2004 2005–2008
(n=101) (n=152) (n=182)
A A 72 (71.2%) 127 (83.5%) 80 (44%)
A A 1 (1%) 23 (15.1%) 94 (51.7%)
A A – 1 (0.7%) 3 (1.6%)
A A – – 5 (2.7%)
A A 3 (3%) 1 (0.7%) –
A A 2 (2%) – –
A A 4 (4%) – –
A A 4 (4%) – –
A A 14 (13.8%) – –
A A 1 (1%) – –
0.7% to 4.3% after the introduction of sulfadoxine–pyrimethamine as the ﬁrst-line
osition 437G and also that of triple pfdhfr/pfdhps (R59N108/G437) mutant haplotypes
.
Fig. 1. Frequency distribution of the combination pfdhfr/pfdhps haplotypes obtained
from isolates collected in Sistan and Baluchistan of Iran before (2000–2004) and after
(2005–2008) the introduction of sulfadoxine–pyrimethamine as the ﬁrst-line
antimalarial treatment. The 10 haplotypes are labeled A to J. dhfr/dhps as follows:
A = N51R59N108I164/S436A437K540A581A613; B = N51R59N108I164/S436G437K540A581A613;
C = I51C59N108I164/S436A437K540A581A613; D = I51C59N108I164/S436G437K540A581A613;
E = N51C59N108I164/S436A437K540A581A613; F = N51C/R59N108I164/S436A437K540A581A613;
G = N51R59S/N108I164/S436A437K540A581A613; H = N/I51R59N108I164/S436A437K540A581
A613; I = N51R59N108I164/S436A/G437K540A581A613; J = N/I51R59N108I164/S436A/G437K540
A581A613; mutated amino acids are shown in boldface type.
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164 (Table 1).
In the case of the pfdhps gene, polymorphisms in different loci of
dhps (A436F/A, A437G, K540E, A581E and A613S/T) were
investigated. All isolates were found to carry wild-type amino
acids at positions 436, 540, 581, and 613, while 437G mutation in
pure formwas detected in 54.4% examined samples collected from
Chabahar districts (Table 1). Mutations at codons 59R, 108N of
pfdhfr with pfdhps 437G were detected in 51.7% of examined
samples (Table 1).
3.3. Distribution of pfdhfr and pfdhps haplotypes before and after the
introduction of sulfadoxine–pyrimethamine
Combinations of pfdhfr and pfdhps haplotypes among all 182
samples in this study demonstrated 4 distinct haplotypes (Table 1).
The two most prevalent haplotypes were N51R59N108/A437 (44%)
and N51R59N108/G437 (51.7%).
Table 2 and Fig. 1 show a comparison of pfdhfr/pfdhps haplotypes
among Iranian P. falciparum isolates before and after the introduc-
tion of SP. The analysis of the samples collected from Chabahar
districts during 2000–2002 (n = 101),24 2003–2004 (n = 152),20 and
2005–2008 (n = 182) showed that mutations were detected at
positions 51, 59 and 108 of dhfr and 437 of dhps in all analyzed
samples. Most of the mutations were in mixed forms in the years
2000–2002, but in pure form after that time (Table 2). During the
years 2000–2002, the most prevalent haplotypes were N51R59N108/
A437 (71.2%) and N51R59N108/A437G (13.8%); however, N51R59N108/
A437 (83.5% and 44%) and N51R59N108/G437 (15.1% and 51.7%) were
the most frequent haplotypes in analyzed samples in the years
2003–2004 and 2005–2008, respectively (Table 2, Fig. 1). A
signiﬁcant increase in the frequency of SNPs at position 437G in
pfdhps was found after three years (Chi-square test, p < 0.0001). In
addition, during 2000–2008 the numbers of haplotypes decreased
from eight to four because of changes in themutated positions from
mixed topure forms. Interestingly,whencombining the two loci, the
frequency of parasites carrying pfdhfr/pfdhps triple pure mutations
(R59N108/G437) increased from 1% in 2000 to 51.7% in 2008 (Chi-
square test, p < 0.0001) (Fig. 1). The two other haplotypes:
I51C59N108/A437 (1.6%) and I51C59N108/G437 (2.7%) were detected in
samples examined in 2008, butwere absent in 2000 (Table 2, Fig. 1).
3.4. Sequence analysis
In this study, based on the different haplotypes detected, 10
isolates were sequenced for both pfdhfr and pfdhps genes. All
isolates were wild at codons 16, 51, and 164 and no newmutations
were detected in the pfdhfr sequence. For the pfdhps gene, the only
mutation detected was at codon 437, with wild-type at other
codons. Similarly, no new mutations were detected in the pfdhps
sequence. These results conﬁrmed the PCR-RFLP analysis.
4. Discussion
The continuous monitoring of SP resistance and resistance to
other antimalarial drugs is of major importance to guide national
malaria treatment policies and also to monitor parasite drug
susceptibility following changes inmalaria treatment policies. This
study was designed to assess the pfdhfr and pfdhps mutations
associated with SP resistance, three years after the introduction of
SP as ﬁrst-line treatment in Iran.
All 182 P. falciparum isolates examined in this study carried the
pfdhfr 108Nmutation (100%) with no evidence of clinical failure to
SP in patients. The results showed 95.7% P. falciparum isolates with
double mutations at codons 59 and 108, indicating the develop-
ment of resistance against antifolate in this region. The doublemutations (I51N108) were detected in only 4.3% of Iranian P.
falciparum isolates, showing an increase from 0.7% to 4.3% after the
introduction of SP as ﬁrst-line drug. Nomutation at codon 164was
detected in any of the examined isolates before or after the
treatment policy changes in Iran. A similar result was obtained for
Indian isolates.25 Furthermore, a signiﬁcant decrease in double
mutations/wild-type of pfdhfr/pfdhps (R59N108/A437) was observed
in Chabahar districts from 2004 (83.5%) to 2008 (44%), showing a
rapid increase in frequency of the single form of pfdhps at position
437G after the changes in treatment policy. In Iran, SP has not been
used widely and has not been used as monotherapy in ﬁrst-line
treatment; it was used as a combination therapy with CQ for only
two years and then replaced with SP/artesunate. In fact, the high
prevalence of mutations in dhfr might be affected by other
chemically related drugs such as co-trimoxazole, which is
commonly used in the study areas for treating bacterial infections
in the setting of malaria in Iran. Therefore, the predominant pfdhfr
haplotype in Iran appears to be N51R59N108 rather than I51R59N108.
The low prevalence of triple mutations in the examined isolates in
this study is similar to the ﬁndings from India,26,27 Sri Lanka28 and
Papua New Guinea;29 however, it is different from the isolates in
Vietnam,30,31 Malaysia,32 Gabon,33 and Brazil,34 where the
predominant haplotype has been found to be I51R59N108. This
may suggest that the pfdhfr allele has evolved independently due to
drug pressure in geographically different regions of the world.
In contrast, most of the P. falciparum isolates (54.4%) revealed a
single haplotype (437G) for pfdhps gene with no mutation at
codons 436, 540, 581, and 613. In addition, three recently reported
mutations at 587, 666, and 668 from Indian P. falciparum isolates
were not detected by sequencing methods among the present
examined isolates, which is in contrast to the work reported by
Garg et al.25 The results showed a rapid increase in frequency of the
single pure form of pfdhps at position 437G and also in triple pfdhfr/
pfdhps (R59N108/G437) mutant haplotype after three years. In our
previous work,20 the prevalence of pfdhps 437G, and also the triple
pfdhfr/pfdhps (R59N108/G437) mutant haplotype, was higher in P.
falciparum isolates collected from Sarbaz (33% and 35.3%,
respectively), in the area of the border with Pakistan, than
Chabahar isolates (17% and 15.8%, respectively) before the
introduction of SP as ﬁrst-line drug. In the present study, three
years after the introduction of SP as ﬁrst-line antimalarial drug, the
frequency distribution of triple mutations has signiﬁcantly
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mutant parasite might have spread through the Indian subconti-
nent to Pakistan and further to Iran. In fact, these results suggest
the establishment of a coordinated network for antimalaria
activities and the standardization of control measures between
two countries, at least in border areas.
The work carried out by Kublin et al.35 showed that quadruple
mutations in dhfr/dhps loci are needed for the parasites to show
clinical failure. Also, a previous study in Mozambique showed that
two mutations at codon 59 in dhfr and codon 437 in dhps were
actually enough to predict SP treatment failure.36 However,
although our results revealed the high prevalence of these two
mutations in Iranian P. falciparum isolates, this has not yet reached
a level at which SP will completely fail in the treatment of patients.
In fact, the results of SP/artesunate efﬁcacy in 75 patients (follow-
up for 28 days) might support this suggestion. In addition, the
present results were in accordance with our previous ﬁndings20 in
which double mutations at codon 59R/108N rather than 51I/108N
were prevalent in our parasite isolates. Therefore, 51I mutation
might be a goodmolecular marker for the triple mutant, indicating
a failure of pyrimethamine in Iran and also the Indian sub-
continent. However, the work carried out by Dokomajilar et al.37 in
Burkina Faso showed that dhfr 59R is more important than 51I as a
marker of SP treatment failure. In addition, these two mutations
with the mutation at position 437G in dhps indicate that the P.
falciparum parasite populations have the potential to evolve into
dhfr/dhps quintuple mutant polymorphism in the near future.
Therefore, monitoring the status of dhps alleles as a predictor of the
development of clinical resistance to sulfadoxine should be a high
priority in this region.
In conclusion, the results of this study suggest that SP should
remain the treatment of choice for uncomplicated malaria as a
partner drug to ACT in Iran, but that regular surveillance for SP
resistance should be continued in this country.
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